tirzepatide doctor philly Empowering Patients Tirzepatide Treatment in Philadelphia, PA

Food and Drug Administration (FDA) approved Novo Nordisks blockbuster drug Wegovy to reduce the risk of serious heart problems in obese or overweight adults

We're talking days, not weeks or months

The first time we saw this was during the liraglutide trials where blood pressure reduction occurred within 2 weeks of initiation of therapy, which was before any meaningful weight benefit was demonstrated suggesting that weight loss is not the driver of the blood pressure benefits

The FDA label notes that gastrointestinal adverse reactions occur more frequently during dose escalation

These include losing weight, standing upright after meals, elevating the head of the bed, and avoiding trigger foods

In a randomized controlled trial, the GLP-1R agonist exenatide showed reduced alcohol intake in a subgroup of people with both obesity and alcohol use disorder